Daunorubicin
Brand names,
Daunorubicin
Analogs
Daunorubicin
Brand Names Mixture
Daunorubicin
Chemical_Formula
C27H29NO10
Daunorubicin
RX_link
http://www.rxlist.com/cgi/generic2/daunorubicin.htm
Daunorubicin
fda sheet
Daunorubicin
msds (material safety sheet)
Daunorubicin
Synthesis Reference
J. P. Parsh et al. J. Pharm. Sci. 56, 1691 (1967);
Daunorubicin
Molecular Weight
527.52 g/mol
Daunorubicin
Melting Point
208-209 oC
Daunorubicin
H2O Solubility
39.2 mg/L
Daunorubicin
State
Solid
Daunorubicin
LogP
0.766
Daunorubicin
Dosage Forms
Powder for solution; Suspension
Daunorubicin
Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunorubicin
Pharmacology
Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
Daunorubicin
Absorption
No information avaliable
Daunorubicin
side effects and Toxicity
LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)
Daunorubicin
Patient Information
Daunorubicin
Organisms Affected
Humans and other mammals